on behalf of the CLWP of the EBMT This randomized-controlled trial studied the efficacy of palifermin in a chemotherapy-only, high-dose Melphalan (HDM) transplant setting, to reduce oral mucositis (OM) and its sequelae measured by patient-reported outcomes (PRO) and medical resource use. Palifermin, relative to placebo was given either pre-/post-HDM or pre-HDM in patients with multiple myeloma (MM) undergoing auto-SCT at 39 European centers. Oral cavity assessment (WHO) and PRO questionnaires (oral mucositis daily questionnaire (OMDQ) and EQ 5D) were used in 281 patients (mean age 56, ± s.d. ¼ 8 years). 57 patients received placebo. One hundred and fifteen subjects were randomized to pre-/post-HDM receiving palifermin on 3 consecutive days before HDM and after auto-SCT and 109 patients were randomized to pre-HDM, receiving palifermin (60 mg/kg/day) i.v. for 3 consecutive days before HDM. There was no statistically significant difference in maximum OM severity. Severe OM occurred in 37% (placebo), 38% (pre-/post-HDM) and 24% (pre-HDM) of patients. No significant difference was observed with respect to PRO assessments or medical resource use, but more infections and fever during neutropenia were reported in pre-/post-HDM vs placebo (for example, 51 and 26%). To conclude, palifermin was unable to reduce OM or OM-related patient's burden in MM transplant patients.
INTRODUCTION
Palifermin (Kepivance),a recombinant human keratinocyte growth factor, is the only drug approved for reduction of incidence, duration and severity of oral mucositis (OM) in patients with hematological malignancies undergoing auto-SCT after myeloablative therapy associated with a high incidence of severe OM. The regulatory approval of palifermin was based on a pivotal phase III study, where patients treated with palifermin in a pre-/post-regimen, experienced significantly less severe OM and needed less opioid analgesics and total parenteral nutrition (TPN). 1 The incidence of severe OM was very high (98%) after a regimen of 1200 cGy TBI, etoposide (60 mg/kg) and CY (100 mg/ kg). Chemotherapy-only conditioning regimens, such as high-dose melphalan (HDM) or BCNU-etoposide-cytarabine-melphalan have a lower incidence of severe OM of 46% and 42%, respectively. 2 This randomized clinical trial was set out to study efficacy, safety and patient's burden of palifermin relative to placebo in HDM-treated patients.
PATIENTS AND METHODS Patients
The institutional review board of 39 study sites approved the protocol; all patients gave written informed consent before any study-related procedure took place. Patients were enrolled if aged between 18 and 70 years, to receive one-day administration of HDM (200 mg/m 2 if creatinine clearance (CC)X30 mL/min or 140 mg/m 2 if CC o30 mL/min) d À 2 auto-SCT, having an Eastern Cooperative Oncology Group (ECOG) PSp2, or an ECOG PS of 3 if the reason for a status 3 was due to multiple myeloma (MM),X2.0 Â 10 6 CD34 þ cells per kg collected, an corrected carbon monoxide diffusing capacityX50% of predicted, an ANCX1.5 Â 10 9 /L and plateletsX100 Â 10 9 /L, total bilirubinp2 mg/dL, and aspartate aminotransferase and/or alanine aminotransferasep4.0 Â institutional upper limit of normal.
Study drug
Study drug, either palifermin 6.25 mg and matching placebo were manufactured and packaged by Amgen Ltd (Cambridge, UK) in identical vials and given as i.v. bolus injections on 3 consecutive days pre-HDM (d À 6, À 5 and À 4) and 3 consecutive days postHDM (d 0, 1 and 2).
Study design
Two hundred and seventy-five patients were planned to be enrolled in this double-blind, placebo-controlled, randomized phase IIIb study. In fact, 281 patients were randomized in a 1:2:2 ratio, respectively; placebo (n ¼ 57), placebo for 3 consecutive days (auto-SCT d À 6, À 5 and À 4) and 3 consecutive days (auto-SCT d 0, 1 and 2), palifermin pre-/post-HDM (n ¼ 115): 60 mg/kg/day i.v. palifermin for 3 consecutive days (auto-SCT d À 6, À 5 and -À 4) before HDM (given on d À 2) and 3 consecutive days (auto-SCT d 0, 1 and 2); palifermin pre-HDM (n ¼ 109): 60 mg/kg/day i.v. palifermin for 3 consecutive days (d À 6, À 5 and À 4) and placebo was given for 3 consecutive days (d 0, 1 and 2).
Randomization was performed by using an interactive-voiceresponse-system before planned admission and stratified by renal function (CCo30 mL/min vsX30 mL/min) and body mass index (o25 vs X25 kg/m 2 ).
Efficacy assessments
Each patient was assessed daily for OM from d À 2 until d À 32 or until discharge. OM-related assessments were the WHO oral-toxicity scale and the patient-reported outcomes (PRO). The WHO scale summarizes OM-related symptoms, signs and functional disturbances; Grade 0 ¼ normal; Grade 1 ¼ soreness and erythema, no further symptoms; Grade 2 ¼ ulcers present, but solid diet possible; Grade 3 ¼ only liquids can be swallowed; Grade 4 ¼ oral alimentation impossible. To achieve high, consistent quality of assessment, nurses and physicians underwent multimedia-assisted face-to-face training including a uniform step-by-step algorithm and case evaluation exercises. PRO was evaluated by the Oral Mucositis Daily Questionnaire (OMDQ) assessing severity and impact of OM by evaluating mouth and throat soreness (MTS) on a five-point scale with higher values indicating a worse MTS, and the degree to which MTS interferes with activities of daily life such as eating, swallowing, drinking, talking and sleeping. Mean daily MTS scores were calculated. All PRO questionnaires, OMDQ and European Quality Of Life Utility Scale (EQ-5D), were to be conducted before oral cavity assessments. OMDQ is validated in HSCT recipients. 3 The EQ-5D is a well validated utility scale (0 ¼ worst imaginable health; 10 ¼ best imaginable health), to compare the effect of interventions.
Healthcare resource and subject burden associated with OM was measured by incidence and duration of: febrile neutropenia; use of i.v. antiinfectives, nonopioid and opioid drugs; TPN; blood product use; days of hospitalization; incidence of significant infections and time to ANC recovery.
Maximum severity of OM (WHO grades 0/1, 2, 3 or 4) was the primary efficacy end point. Secondary efficacy end points included incidence and duration of ulcerative OM (WHO grades 2, 3 and 4), incidence and duration of severe OM (WHO grades 3 and 4), area under the curve for MTS and patient-reported MTS limitations. Tertiary efficacy end points included the healthcare resource use as stated above including EQ-5D.
Safety assessments
Safety was assessed by physical examination (including daily body temperature), recording of medications, transfusions, vital signs, laboratory assessments (hematology, chemistry) and adverse events (AEs).
The safety end point was incidence of all AEs (including serious AEs, severe and treatment-related AEs) and laboratory abnormalities using CTC version 3.0 toxicity scale).
Statistical analysis
The null hypothesis was that the severity distribution for OM was identical for the placebo group and for each of the palifermin groups. The alternative hypothesis was that treatment with palifermin resulted in a distribution shift to less severe mucositis as opposed to placebo. Using a proportional odds model, a total of 275 subjects would give at least 95% power, with an overall type I error rate of 5% to detect an odds ratio (OR) of at least 3.5 between placebo and palifermin. For example, if the incidence of ulcerative OM (WHO grades 41) in the placebo group is 67%, an OR of 3.5 corresponds to a 30% reduction in incidence of OM (that is, 67% vs 37%). Distribution of OM severity was based upon the POMA study. 2 The power was estimated using Monte Carlo simulation with 10 000 replicates giving an estimated 95% confidence interval (CI). Treatment comparisons between placebo and palifermin groups was made at an alpha level of 0.025 to protect the overall two sided type I error rate of 0.05. Point estimates of treatment differences were accompanied by corresponding 97.5% CIs.
A proportional odds model, including randomization factors as covariates was used as primary analysis method. The Hochberg procedure 4 was used to adjust for multiple testing for secondary end points, the stratified Cochran-Mantel-Haenszel w 2 test for comparison of incidence of severe and ulcerative OM and for all tertiary end points, the van Elteren test 5 for duration of severe and ulcerative OM and MTS limitations. Time to ANC recovery was analyzed using the Kaplan À Meier method and a stratified log-rank test for treatment comparison. Descriptive statistics were used to summarize blood product use by incidence and total volume of blood product. The full analysis set included all randomized subjects, and the safety subset included all randomized subjects who received at least one dose of the investigational product.
RESULTS

Patients
Between 28 December 2006, and 27 February 2009, a total of 281 randomized patients were included: 57 in the placebo group, 115 in the pre-/post-HDM group and 109 in the pre-HDM group ( Figure 1 ). Twenty-four patients discontinued because of AEs, consent withdrawal and other (for example, assessments not done, unplanned discharge and inability to travel to end of study visit). Groups were well matched with regard to baseline demographic characteristics (Table 1) . Overall, median age was 57 years (min 32, max 69). Approximately 55% of patients were Full analysis set a (n = 57) Full analysis set a (n = 115) Full analysis set a (n = 109) a Full analysis set included all randomized subjects. subjects were included in the treatment group to which they were randomized. b Safety subset included all subjects that received at least 1 dose of lP. subjects randomized to the placedo or to the pre-HDM group who received one or more doses of palifemin post-HDM were included in the pre/ post-HDM treatment group. subjects randomized to placebo who received 1 or more doses of palifermin pre-HDM, but none post-HDM are included in the pre-only treatment group. subjects randomized in the pre/post-HDM group who received palifermin only pre-HDM were included in the pre-HDM treatment group. missing. There were no notable differences with respect to laboratory baseline parameters (b 2 -microglobulin, hemoglobin, platelets, white blood cells, creatinine, CC and 24-h urine CC). Over 87% of patients received the required number of doses of the investigational drug during study and 97% were exposed to HDM, with no notable differences between treatment arms or randomization strata. There was no notable difference in either median number of CD34 þ cells re-infused or mobilization method.
Efficacy end points
There was no statistically significant difference in the primary efficacy end point, maximum severity of OM between placebo and palifermin given either pre-/post-HDM (OR: 0.7 (CI: 0.4, 1.3)) or pre-HDM OR: 1.2 (CI: 0.6, 2.4) (Figure 2 ). However, there was a numerical difference in favor of palifermin in pre-HDM compared with placebo for the primary and most of the secondary efficacy end points (Table 2) , such as incidence of severe OM (24% vs 37%), mean duration of severe OM (1.9 vs 2.4 days), incidence of ulcerative OM (51% vs 58%) as well as mean duration of ulcerative OM (4.8 days pre-HDM, 5.0 days placebo). Patient-reported MTS was in line with OM assessments (Table 2 ). Mean OM grade over time is presented graphically in Figure 3 . Peak of mean OM was observed on day 9 for all groups. Strikingly, an increase in mean OM was already observed on day 0-4 in pre-/ post-HDM, but not in the other arms. The mean area under the curve of MTS showed exactly the same picture.
No association was identified between maximum OM severity and gender, b 2 -microglobulin, tobacco or alcohol use. Only, CC at baseline was found to have a slight influence on severity of OM (OR 1.16 (CI: 1.02, 1.33)). Additional post-hoc efficacy analyses showed a larger difference, albeit not significant between palifermin and placebo in incidence of severe OM in patients dosed with melphalan above 5.25 mg/kg.
Healthcare use and patient burden are depicted in Table 3 . The incidence of febrile neutropenia was higher in the pre-/post-HDM group (34%) than in the pre-HDM (25%) or placebo (26%) groups but the mean duration of febrile neutropenia was not different (1.1,1.6 and 1.3 days for placebo, pre-/post-HDM and pre-HDM groups respectively). The incidence and mean duration of anti-infective drug use was similar in all arms (75%, 77%, 73% and 21, 18, 20 days for placebo, pre-/post-HDM and pre-HDM, respectively). The most commonly used drugs were acyclovir, fluconazole and ciprofloxacin. Nonopioid analgesic use was similar (100, 98 and 99% in placebo, pre-/post-HDM and pre-HDM, respectively). The median duration of nonopioid analgesic use by patients experiencing this event, was 39 days in all arms. The use of opioids was lower in the pre-/post-HDM and pre-HDM groups compared with the placebo group, especially strong opioids were significantly less used in the pre-HDM group (P ¼ 0.04). Significantly more patients in the pre-/post-HDM group received TPN than those in the placebo group (61% vs 40%, and TPN was administered for notably longer (mean difference of 3.9 days). The majority of patients (up to 77%) used blood products with no major differences between the groups. Mean duration of hospitalization was 23 days in all arms. The median time to ANC recovery of 40.5 Â 10 9 L was 11 days in all groups. In general, more infections, defined as clinical or microbiologically with or without bacteremia and fever of unknown origin, were reported in pre-/post-HDM than in placebo (52% vs 27%) as AEs (see below).
The mean EQ-5D health utility score reporting on mobility, elf-care, usual activities, pain/discomfort and anxiety/depression Group 1-Serum 2 -microglobulin o3.5 mg/L Serum albumin ¼ 3.5 g/dL; Group 2-Not stage I or III; Group 3-Serum 2 -microglobulin ¼ 5.5 mg/L. There were two categories for group 2: serum 2 -microglobulin o3.5 mg/L but serum albumin 43.5 g/dL; or serum 2 -microglobulin 3.5 to o5.5 mg/L irrespective of the serum albumin level. Safety end points A total of 275 patients (99.3%) experienced at least one AE with no notable differences in incidence of AEs between arms (Table 4) . AEs were separated into reported before and after HDM. Before HDM, AEs of skin and s.c. tissue (rash, erythema and peripheral edema) were most frequently reported in palifermin groups (pre-/ post-HDM 32% and pre-HDM 32%) vs placebo (12%). After HDM, rash was more often seen in the pre-/post-HDM group (38%) than in the placebo (21%) or pre-HDM groups (22%). More patients suffered from treatment related AEs in the pre-/ post-HDM group (72%), vs the placebo (30%) or pre-HDM groups (57%), but the majority was ograde 3. More oral related AEs were reported in the pre-/post-HDM (28%) and pre-HDM groups (28%) than in the placebo group (12%). Oral herpes (6% vs 0%), oral fungal infections (6% vs 2%) and sepsis (9% vs 2%) were more reported in palifermin groups compared with placebo. However, bacteremia was less frequent in palifermin groups compared with placebo (1% vs 4%).
Two patients died during the study, one in the pre-/post-HDM and one in the pre-HDM group. Both deaths occurred after HDM.
DISCUSSION
In this study, palifermin did not prevent OM nor reduced OMrelated patient burden in auto-SCT patients prepared with chemotherapy-only conditioning, being HDM. There was a numerical indication of a treatment effect for pre-HDM on maximum severity of OM, on incidence (relative reduction of 1/ 3) and duration of OM and on less strong opioid drug use. On the contrary, the use of palifermin in a pre-/post-HDM setting aggravated clinically meaningfully both oral toxicity and OMrelated patient burden.
These efficacy results are not in line with previous clinical studies with palifermin in patients with hematological malignancies. 1, 6, 7 However, there is a significant difference between study designs regarding conditioning regimens used and timing of palifermin. According to the label, timing of palifermin is set in relation to start (predose) and end (postdose) of myeloablative therapy and not within 24 h before start of conditioning. Palifermin given before initiation of cell damage induces a transient increase in proliferation and differentiation of epithelial cells, resulting in mucosal layer thickening. 8 Palifermin post dose promotes wound re-epithelialisation or healing as shown in keratinocyte growth factor receptor knockout mice that had reduced wound re-epithelialisation. 9 Conditioning regimens are usually administered over several days and entail different drugs or are combined with TBI, and with HDM as exception. The interval between pre-and post doses of palifermin is only 4 days in HDM compared with 8 days in the pivotal study. This short interval results in a post dose given probably too early relative to the peak of OM, a complex biological process, culminating in maximum ulcerative breakdown of the epithelial layer 10 À 14 days after initiating conditioning. 10 Mean OM score reached Grade 1 on day 0 in the pivotal study compared with day 4 in the HDM study. So, suboptimal timing of the postdose may impair healing and can exaggerate oral toxicity.
In murine models, increased thickness of epithelium persisted forX4 days after the last of three keratinocyte growth factor injections. 11 Maximal proliferation of epithelial cells in buccal samples of healthy volunteers was seen 48 h after a single-dose of palifermin. 12 Increased expression of cyclin-E, a putative G1 marker together with increased levels of Ki-67 were seen in Table 2 . Secondary efficacy end points of palifermin vs placebo buccal mucosal biopsies of patients with sarcoma after 48-72 h of palifermin dosing. 13 Therefore, the exceptionally short interval of pre-and postdosing of palifermin in this study resulted in an overlapping and exaggerated pharmacological effect of hyperkeratosis. This hyperkeratosis can easily be misinterpreted as OM or a clinically defined infection 14 and is probably the explanation of a higher rate of oral AE's in the pre-/post-HDM group. Both patient-reported MTS and professional documented OM score indicate an early OM peak (auto-SCT days 0-4) in the pre-/post-HDM group, (depicted in Figure 3 ) which is inconsistent with the well-established course of chemotherapy-induced OM. The other reported AEs for palifermin-treated patients were not different from previous clinical studies and post marketing surveillance. However, the increase of clinical oral herpes infections is a new finding, whereas increased frequencies of oral fungal infections and sepsis after palifermin have been reported earlier. 1 Reactivation of basal epithelial cells containing viruses by palifermin is suggested. 15 In a retrospective cohort study, severe OM was 24% after a 3-day course of palifermin preceding HDM, comparable with the result in the pre-HDM arm. 16 The third dose was given 2 days before HDM without increasing toxicity. In contrary to our study, palifermin prophylaxis reduced significantly days of hospitalization, use of parenteral nutrition and narcotics, and need for erythrocyte transfusions but OM data were not available for the historical control group. Previous analysis of the pivotal phase III study with palifermin reduced, albeit not significantly the cost of care with mean savings of $3595 per patient in those patients who received palifermin.
17 A 1-day dosing of palifermin just before admitting a patient to prepare for auto-SCT would not only be patient friendly but will optimize cost-effectiveness if shown efficacious in properly selected patients. Doses up to 180 mg/kg have been tested safe in healthy volunteers. One-day dosing of palifermin of 180 mg/kg, 3 days before cycled doxorubicin-based chemotherapy was efficacious in reducing severe OM in sarcoma patients from 51 to 13%. 13 Besides, the Palifermin and oral mucositis after HDM N Blijlevens et al importance of timely dosing of a potent drug, the expected incidence of severe OM is crucial. Palifermin significantly reduced severe OM from 100 to 81% after CY and TBI but not after BU and CY (50% vs 44%) in allogeneic transplant recipients. 6 In a matched controlled retrospective study only ulcerative OM was significantly reduced from 86 to 60% in allo-grafted patients, mainly after CY/TBI. 18 A recent retrospective study reported only a significant effect of palifermin on OM-sequelae (use of TPN and analgesia) in TBI-treated allogeneic patients. 19 In summary, there are several possible explanations for the negative result of palifermin in this study; suboptimal timing of the post-dose (too early after HDM and the pre-dose) negatively influenced repair and also exaggerated hyperkeratosis misinterpreted as OM. One can argue if post dosing is necessary in chemotherapy-only settings. Moreover, in settings where the incidence of OM is unexpectedly lower as in the placebo group, it tends to be harder to show a statistically significant effect on OM.
OM requires significant health-care resources and in these times of parsimony it is surely worth knowing which interventions do not lead to better patient outcomes, if only to spare resources. The European Medicines Agency has restricted recommendation based on results of this trial, for the use of palifermin to auto-SCT patients prepared with chemo-radiotherapy associated with a high incidence of OM. But OM is still an unmet medical need and burdensome toxicity in auto-SCT patients as indicated by PRO, with only very few alternatives. Only cryotherapy is suggested (level II, A) to prevent OM in patients receiving HDM. 20 Incorporating known predictive risk factors of OM to target only those patients who will benefit the most of interventions aimed at reducing OM and its related burden is mandatory. 21 In conclusion, regular palifermin should not be used in MM patients receiving HDM.
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